Special Offers & Promotions
Laboratory Automation & IT Solutions
PerkinElmer launches next-generation cell image analysis and management software to streamline drug discovery decision-making
Signals Image Artist platform helps scientists process and analyse 3D cell imaging, phenotypic and cell painting data in a matter of hours, rather than days or weeks
PerkinElmer, Inc., a global leading solutions provider in the life sciences, diagnostics, food and environmental testing markets, has announced the launch of Signals Image Artist™ software – a next-generation image analysis and management platform for drug discovery research.
The new offering is designed to help scientists accurately process and analyse their high-content screening (HCS) and cellular imaging data in a matter of hours, instead of days or weeks, so they can make more informed decisions faster. The Signals Image Artist offering is part of PerkinElmer’s leading Signals Informatics portfolio.
Signals Image Artist is designed for the big data demands that drug discovery labs are working with today, including 3D cell, phenotypic and cell painting images. Its intuitive user interface requires minimal user training and the software supports multiple users processing, analysing, sharing and storing information at the same time, without compromised performance.
Cloud and on-premise deployment options are available, as is scalable storage capacity to expand as lab needs change.
Alan Fletcher, senior vice president of life science at PerkinElmer, said: “Today’s drug discovery labs are generating massive amounts of image data, driven by a rise in the use of physiologically relevant models and the increasing adoption of cell painting and phenotypic screening approaches to try and reduce clinical trial failure rates.
“Our Signals Image Artist platform will help drug discovery researchers drive more efficiently and effectively towards the next new novel therapeutic candidate, by dramatically speeding up image processing, delivering quick and accurate data, and fostering easier collaboration.”
Chris Hughes, managing director UK & Ireland at PerkinElmer, added: “We’re really excited about the launch of this new, cutting edge software, which builds on our industry-leading array of high content screening instruments and reagents. This latest offering will fully support the big data lab demands of today and tomorrow.”
High Content Screening
The new software is a strong complement to PerkinElmer’s HCS workflow solution that includes the Opera Phenix® Plus and Operetta® CLS High-Content Screening System, PhenoVue™ reagents, PhenoPlate™ microplates, automation and Signals Screening™ platform (soon to be rebranded Signals VitroVivo™).
The pre-built integration of the Signals Image Artist software means users of the Signals VitroVivo platform can make a seamless handover of data coming from HCS experiments to perform secondary analysis like machine learning-supported clustering and statistical analysis. This integration helps scientists gain insights into time series, potential treatment and phenotypic changes in the drug candidates they are working on, and enables results and supporting workflows to be shared.
The Signals Image Artist software is also compatible with all major HCS and cell imaging systems on the market today, supporting users in multi-vendor lab environments.
PerkinElmer’s HCS solutions are part of a comprehensive portfolio for life science and drug discovery and development.
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 15,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.